share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  2024/08/13 20:02

Moomoo AI 已提取核心訊息

BioCardia reported Q2 2024 financial results, with revenue decreasing to $3,000 from $43,000 in Q2 2023. Net loss narrowed to $1.65 million from $3.42 million year-over-year. Research and development expenses decreased to $800,000 from $2.31 million, while selling, general and administrative expenses fell to $852,000 from $1.18 million.For the first half of 2024, revenue declined to $58,000 from $107,000 in H1 2023. Net loss improved to $3.91 million from $6.93 million. The company ended Q2 with $1.42 million in cash and cash equivalents. BioCardia cited reduced personnel expenses and clinical staff reductions following enrollment completion in its CardiAMP Cell Therapy Heart Failure Trial as key factors for the decreased expenses.BioCardia faces liquidity concerns, with management stating current cash is insufficient to fund operations through September 2024. The company plans to raise additional capital through various means to continue operations and development programs. BioCardia is also working to regain compliance with Nasdaq listing requirements by September 2, 2024 to avoid potential delisting.
BioCardia reported Q2 2024 financial results, with revenue decreasing to $3,000 from $43,000 in Q2 2023. Net loss narrowed to $1.65 million from $3.42 million year-over-year. Research and development expenses decreased to $800,000 from $2.31 million, while selling, general and administrative expenses fell to $852,000 from $1.18 million.For the first half of 2024, revenue declined to $58,000 from $107,000 in H1 2023. Net loss improved to $3.91 million from $6.93 million. The company ended Q2 with $1.42 million in cash and cash equivalents. BioCardia cited reduced personnel expenses and clinical staff reductions following enrollment completion in its CardiAMP Cell Therapy Heart Failure Trial as key factors for the decreased expenses.BioCardia faces liquidity concerns, with management stating current cash is insufficient to fund operations through September 2024. The company plans to raise additional capital through various means to continue operations and development programs. BioCardia is also working to regain compliance with Nasdaq listing requirements by September 2, 2024 to avoid potential delisting.
BioCardia公佈了2024年第二季度財務業績，營業收入從2023年第二季度的43000美元降至3000美元。淨虧損從342萬美元減少至165萬美元。研發費用從231萬美元降至80萬美元，而銷售、一般和行政費用從118萬美元降至85.2萬美元。在2024年上半年，營業收入從2023年上半年的107000美元降至58000美元。淨虧損從693萬美元改善至391萬美元。公司在第二季度結束時擁有142萬美元的現金及現金等價物。BioCardia指出，隨着其CardiAMP電芯治療心力衰竭試驗的入組完成，人員費用減少和臨牀工作人員的削減是開支減少的關鍵因素。BioCardia面臨流動性問題，管理層表示目前的現金不足以支持運營到2024年9月。公司計劃通過多種方式融資以繼續運營和開發項目。BioCardia還在努力在2024年9月2日前重新符合納斯達克上市要求，以避免潛在的退市。
BioCardia公佈了2024年第二季度財務業績，營業收入從2023年第二季度的43000美元降至3000美元。淨虧損從342萬美元減少至165萬美元。研發費用從231萬美元降至80萬美元，而銷售、一般和行政費用從118萬美元降至85.2萬美元。在2024年上半年，營業收入從2023年上半年的107000美元降至58000美元。淨虧損從693萬美元改善至391萬美元。公司在第二季度結束時擁有142萬美元的現金及現金等價物。BioCardia指出，隨着其CardiAMP電芯治療心力衰竭試驗的入組完成，人員費用減少和臨牀工作人員的削減是開支減少的關鍵因素。BioCardia面臨流動性問題，管理層表示目前的現金不足以支持運營到2024年9月。公司計劃通過多種方式融資以繼續運營和開發項目。BioCardia還在努力在2024年9月2日前重新符合納斯達克上市要求，以避免潛在的退市。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間